NeoGenomics(US:NEO)2021-05-06 08:59Company Overview - NeoGenomics is a leading oncology diagnostic company with a diversified "One Lab" approach[12] - The company has three synergistic divisions with double-digit growth profiles: Clinical Services, Pharma Services, and Informatics[12] - In 2020, Clinical Services accounted for 85% of the company's revenue, while Pharma & Informatics accounted for 15%[14] Financial Performance (FY 2020) - Revenue was $444 million, representing a 9% growth rate[15] - The company performed 976,069 core clinical tests[15] - Adjusted EBITDA was $35 million[15] Market Trends - The oncology testing market is estimated to grow at an annual rate of 6% to 8%[23] - The number of cancer survivors is projected to increase by 31.4% to 22.2 million by 2030[29] - The late-phase targeted therapy oncology pipeline increased 100% from 2008 to 2018[40] Pharma Services - The company recorded $31 million in new signed contracts in Q1 2021[68] - The company exited Q1 2021 with a record $218 million backlog[68] Q1 2021 Financials - Total revenue was $115.533 million, with Clinical Services contributing $96.487 million and Pharma Services contributing $19.046 million[101] - Net loss was $22.114 million[101] - Adjusted EBITDA was $4.186 million[109]